In the past, comparative proteomic studies using total muscle tissue extracts have greatly helped to improve our general understanding of the molecular pathogenesis of dystrophinopathies, but have mostly focused on alterations downstream of the dystrophin-glycoprotein complex. The gene discussed is DMD; the disease is neuromuscular disease caused by qualitative or quantitative defects of dystrophin.